Skip to main content

Table 4 Grade 3/4 events in the whole population (N = 248)

From: Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

Toxicities XELOX group
(N = 159)
DOS group
(N = 89)
P
leukocytopenia 6 (3.7) 3 (3.4) 0.848
Febrile neutropenia 1 (0.6) 0 (0) 0.768
thrombocytopenia 5 (3.1) 3 (3.4) 0.781
anemia 2 (1.3) 0 (0) 0.747
nausea 2 (1.3) 1 (1.1) 0.608
vomiting 1 (0.6) 1 (1.1) 0.747
diarrhea 1 (0.6) 0 (0) 0.768
hand-foot skin reaction 3 (1.9) 1 (1.1) 0.945
hepatic dysfunction 2 (1.3) 1 (1.1) 0.608
neuropathy 2 (1.3) 0 (0) 0.747
Mucositis 3 (1.9) 1 (1.1) 0.946